Central Precocious Puberty: Treatment with Triptorelin 11.25 mg

Table 3

Efficacy of LH peak suppression of long-acting GnRH analogs in CPP (short- and medium-term studies in de novo-treated children).

		Sex			Patients with optimal LH suppression, %
Author	GnRH analog	F, 𝑛	M, 𝑛	Cutoff LH peak,  IU/L	3 months	6 months	9 months	12 months
Carel et al. [6]	Leuprorelin 11.25 mg	40	4	3.0	93.0	98.0	—	—
Meriq et al. [16]	Leuprorelin 11.25 mg	10	1	3.0	—	—	—	88°
Carel et al. [7]	Triptorelin 11.25 mg	54	10	3.0	85.0(97^∧)	97(97^∧)	—	95(97^∧)
Martínez-Aguayo et al. [8]	Triptorelin 11.25 mg	19	1	3.0	90.0	100	100	100^§
Trueman et al. [17]	Goserelin 10.8 mg	23	6	1.7	67.0	—	—	—
Isaac et al. [18]	Goserelin 10.8 mg	23	5	2.0	—	—	—	81*
Lewis and Eugster [19]	Histrelin 50-mg	20	—	4.0	100	100	100	100°°
Present study	Triptorelin 11.25 mg	16	—	3.0	100^∧∧	100^∧∧	100^∧∧	100^∧∧

°data at 18 months of leuprorelin administration.
^∧data in peer-protocol population (𝑛=37 patients who had received all doses of triptorelin 11.25 and without no major protocol violation).
^§LH peak below 3.0 IU/L was documented at 15, 18, and 21 months of followup. At month 24, 1 patient showed a leak peak at 3.0 IU/L.
*20/28 (71%) required treatment injections at 6–10 weekly intervals.
°°data were confirmed in the 12–24 months of followup [20].
^∧∧using the lower cutoff value of 2.0 IU/L [18], the percentage of patients with optimal suppression did not change.